1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)

Authors :: Stellato, M.
Buti, S.
Maruzzo, M.
Bersanelli, M.
Ermacora, P.
Maiorano, B.A.
Prati, V.
De Giorgi, U.F.F.
Pierantoni, F.
Malgeri, A.
Mennitto, A.
Cavo, A.
Vitale, M.G.
Santoni, M.
Carella, C.
Procopio, G.
Verzoni, E.
Santini, D.
Source :: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1214-S1215. 2p.
Publication Year :: 2022

Subjects :: *RENAL cell carcinoma
*SUBGROUP analysis (Experimental design)
*TREATMENT effectiveness
*METASTASIS
*PEMBROLIZUMAB

Full Text Access

Tools